Cover Image
Market Research Report

China Pharmaceuticals & Healthcare Q3 2019

Published by Fitch Solutions, Inc. Product code 209173
Published Content info 96 Pages
Delivery time: 1-2 business days
Back to Top
China Pharmaceuticals & Healthcare Q3 2019
Published: May 14, 2019 Content info: 96 Pages

Key View:

China remains one of the most attractive APAC markets for innovative drugmakers. In the coming years, the Chinese pharmaceutical market will grow modestly with medicine sales driven an ageing population and high disease burden. New regulatory pathways and improvements to China's drug approval process will bolster long-term growth opportunities for drugmakers. Although this is favourable to innovative drugmakers, patented drug sales will be limited by the government's drug pricing and reimbursement policies as well as other cost-containment measures.

Table of Contents
Product Code: SSCN03_20190701

Table of Contents

  • Key View
  • SWOT
  • Industry Forecast
  • Pharmaceutical Market Forecast
  • Healthcare Market Forecast
  • Prescription Drug Market Forecast
  • Patented Drug Market Forecast
  • Generic Drug Market Forecast
  • OTC Medicine Market Forecast
  • Pharmaceutical Trade Forecast
  • Industry Risk/Reward Index
  • Asia Pacific Innovative Pharmaceuticals Risk/Reward Index
  • Innovative Pharmaceuticals Risk/Reward Index
  • Regulatory Development
  • Regulatory Review
  • 13th Five-Year Plan: Key Points
  • Market Overview

Competitive Landscape

  • Company Profile
  • AstraZeneca
  • Bayer HealthCare
  • China Shijiazhuang Pharmaceutical Group (CSPC)
  • Eli Lilly (Lilly China)
  • GlaxoSmithKline
  • MSD
  • Merck KGaA
  • North China Pharmaceutical Corporation
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceuticals Holding Co
  • Sinopharm
  • China Demographic Outlook
  • Pharmaceuticals & Healthcare Glossary
  • Pharmaceuticals & Healthcare Methodology
Back to Top